Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Immunotherapy has gained a significant amount of attention recently, but its efficacy as a
single agent in gynecological cancers has been disappointing. Pre-clinical evidence supports
the combination of using Vascular Endothelial Growth Factors (VEGF) inhibitors with
immunotherapy. VEGF inhibitors suppress the activation of tumor-associated macrophages (TAMs)
and VEGF has been shown to affect the functional maturation of dendritic cells; therefore,
VEGF inhibitors could improve the function of antigen presentation. In this study,
Cabozantinib (VEGF inhibitor) and Dostarlimab (immunotherapeutic drug) will be admnistered as
a combination to patients with recurrent gynecologic carcinosarcoma.